Fueling NK cell cytotoxicity and cytokine release in the context of virotherapy via BiKE engagement might therefore support anti-tumor effects beyond NK cell-dependent killing, specifically OV-induced tumor vaccination effects. The gene discussed is BMP2K; the disease is neoplasm.